光动力疗法可以使用替拉泊芬钠作为中央型早期肺癌的日间治疗安全进行。
Photodynamic therapy can be safely performed with Talaporfin sodium as a day treatment for central-type early-stage lung cancer.
机构信息
Department of Endoscopy, Respiratory Endoscopy Division, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
Department of Endoscopy, Respiratory Endoscopy Division, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
出版信息
Photodiagnosis Photodyn Ther. 2022 Jun;38:102836. doi: 10.1016/j.pdpdt.2022.102836. Epub 2022 Mar 30.
BACKGROUNDS/AIM: Photodynamic therapy (PDT) with Talaporfin sodium (Talaporfin) is an effective and safe treatment for central-type early-stage lung cancer (CELC) that is associated with less skin photosensitivity. However, PDT is mostly performed in hospital for the purpose of light shading management in Japan. It is expected that it will be possible to perform PDT with Talaporfin (Talaporfin-PDT) as a day treatment with ≥14 days of shading management at home. This study aimed to confirm the safety of Talaporfin-PDT as day treatment.
METHODS
We retrospectively investigated the occurrence of adverse events among consecutive patients who received PDT for CELC in a day treatment setting in the Respiratory Endoscopy Division of our institution between January 2010 and February 2020.
RESULTS
A total of 12 patients (16 treatments) received day treatment of Talaporfin-PDT. Among the 12 patients, one patient (one treatment) was followed at another hospital. No severe adverse events after treatment were observed among the remaining 11 patients (15 treatments). Mild photosensitivity on a photosensitivity test was observed in 3 (3 treatments) of the 11 patients (15 treatments) but no major photosensitivity was observed. This photosensitivity was a temporary reaction.
CONCLUSION
Talaporfin-PDT for CELC was safely performed as a day treatment.
背景/目的：使用替拉扎明钠（Talaporfin）进行光动力疗法（PDT）是治疗中央型早期肺癌（CELC）的有效且安全的方法，其皮肤光过敏反应较轻。然而，在日本，PDT 主要在医院进行，目的是进行光遮蔽管理。预计使用替拉扎明（Talaporfin）进行 PDT（Talaporfin-PDT）可以作为一种日间治疗，患者在家中进行 ≥14 天的遮蔽管理。本研究旨在确认 Talaporfin-PDT 作为日间治疗的安全性。
方法
我们回顾性调查了我院呼吸内镜科 2010 年 1 月至 2020 年 2 月连续接受 CELC PDT 日间治疗的患者发生不良事件的情况。
结果
共 12 例（16 次治疗）患者接受了 Talaporfin-PDT 日间治疗。12 例患者中，1 例（1 次治疗）在其他医院进行了随访。其余 11 例（15 次治疗）患者均未观察到治疗后严重不良事件。11 例（15 次治疗）中有 3 例（3 次治疗）轻度光敏性测试阳性，但未观察到严重光敏性。这种光敏性是一种暂时的反应。
结论
替拉扎明钠治疗 CELC 的 PDT 可安全地作为日间治疗进行。
Zotero 插件